REGENXBIO Inc. announced on March 4, 2025, the closing of its strategic partnership with Nippon Shinyaku. This partnership focuses on the development and commercialization of RGX-121 for Mucopolysaccharidosis II (MPS II) and RGX-111 for Mucopolysaccharidosis I (MPS I) in the United States and Asia.
The closing of this agreement confirms the previously announced terms, which include an upfront payment to REGENXBIO and potential future milestones and royalties. RGX-121 is on track for potential FDA approval as early as late 2025.
This collaboration is expected to bolster REGENXBIO's ability to advance these programs and serve the MPS community, leveraging Nippon Shinyaku's expertise in rare diseases and commercial capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.